Mohawk Industries
MHK
$126.09
-1.79%
Mohawk Industries, Inc. is the world's largest flooring manufacturer, producing carpet, rugs, ceramic and porcelain tile, laminate, wood, luxury vinyl tile (LVT), and vinyl flooring through three reporting segments: Global Ceramic, Flooring North America, and Flooring Rest of the World. The company operates a vertically integrated, multi-brand platform (including Mohawk, Pergo, Quick-Step, and Marazzi) with roughly 40,500 employees and a manufacturing and distribution footprint spanning the United States, Europe, Latin America, and other regions, giving it a scale advantage few competitors can match. The current investor narrative centers on a cyclical housing-recovery thesis: after a multi-year downturn in residential remodeling and new construction, Mohawk's most recent quarter showed revenue growth of 8.0% year over year, its strongest top-line comparison in several periods, fueling debate over whether the flooring cycle has finally inflected. At the same time, the stock is caught between improving volume trends and persistent margin pressure, with gross margin of roughly 23.5% still well below the 25%+ levels of 2024, and a management team that has been leaning on cost actions, restructuring, and share repurchases to defend earnings. Analyst sentiment has turned more cautious recently, with several downgrades to Neutral/Equal Weight since April 2026, even as the consensus recommendation remains Buy, reflecting the tension between a cheap valuation and an uncertain recovery path.…
MHK
Mohawk Industries
$126.09
Investment Opinion: Should I buy MHK Today?
The synthesized recommendation is Hold, with a value tilt. The core thesis is that Mohawk is a deep-value cyclical play trading at a discount to book (P/B 0.81x) and sales (P/S 0.63x), but the recovery is unproven and margin pressure persists. The analyst consensus is Buy with an average target of $135.79, implying 7.1% upside, but the recommendation mean of 2.47 is lukewarm and recent downgrades to Neutral suggest limited near-term conviction.
Supporting evidence includes: 1) Revenue growth of 8.0% YoY in Q1 2026, the strongest in several periods; 2) Forward PE of 12.6x versus trailing 18.3x, implying expected earnings growth; 3) EV/EBITDA of 7.4x, below peers at 8-12x; 4) Conservative balance sheet with debt-to-equity of 0.29 and current ratio of 2.19; 5) Free cash flow TTM of $709.4 million, though Q1 2026 FCF was only $7.8 million due to working-capital build. The stock's P/B of 0.81x is near the low end of its historical range (0.71x-1.54x), which historically has coincided with cyclical troughs.
Key risks that could invalidate the thesis include: 1) Gross margin failing to recover above 23.5%, keeping profitability weak; 2) A stall in the housing recovery, which would pressure revenue growth; 3) Further analyst downgrades if earnings disappoint. The rating would upgrade to Buy if gross margin recovers above 25% and revenue growth sustains above 8%, or downgrade to Sell if gross margin falls below 23% and revenue growth turns negative. The stock appears fairly valued to slightly undervalued relative to its history and peers, but the discount is justified by inferior profitability (net margin 4.3%, ROE 4.4%).
Sign up to view all
MHK 12-Month Price Forecast
Mohawk presents a classic cyclical value opportunity with significant upside if the housing recovery gains traction, but the evidence of a sustainable inflection is still emerging. The 8.0% revenue growth in Q1 2026 is encouraging, yet gross margin compression and weak returns on equity (4.4%) suggest the recovery is fragile. The stock's deep-value multiples (P/B 0.81x, P/S 0.63x) provide a margin of safety, but the forward PE of 12.6x implies the market expects earnings growth that has not yet been proven. Analyst sentiment is lukewarm, with a consensus target of $135.79 offering modest upside and a wide target range ($115-$155) reflecting disagreement. I would upgrade to bullish if gross margin recovers above 25% and revenue growth sustains above 8% for two consecutive quarters; I would downgrade to bearish if gross margin falls below 23% or revenue growth turns negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mohawk Industries's 12-month outlook, with a consensus price target around $135.79 and implied upside of +7.7% versus the current price.
Average Target
$135.79
0 analysts
Implied Upside
+7.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$115 - $155
Analyst target range
Fourteen analysts cover Mohawk, with a consensus recommendation of Buy (recommendation mean of 2.47 on a scale where lower is more bullish) and an average target price of $135.79. Against the current price of $126.79, that implies upside of approximately +7.1% to the consensus target. The sentiment is moderately bullish but not conviction-driven: the recommendation mean of 2.47 sits in the lower half of the Buy/Hold spectrum, and recent institutional actions have skewed cautious — B of A Securities downgraded to Neutral from Buy on April 20, 2026, and Baird downgraded to Neutral from Outperform on April 21, 2026, while Barclays, Wells Fargo, and Evercore ISI have maintained Equal Weight/In Line ratings. The consensus is best characterized as a lukewarm Buy with a value tilt rather than a high-conviction growth call.
The target range spans $115 (low) to $155 (high), a spread of $40, or roughly 32% of the current price — a wide dispersion that signals meaningful disagreement about the recovery's strength. The high target of $155 implies roughly +22% upside and would require multiple expansion (forward PE toward 15x) plus evidence that the 8% revenue growth is sustainable and margins recover toward 25%+. The low target of $115 implies about -9% downside and prices in a stall in the housing recovery, continued gross-margin compression below 23%, and earnings that fail to leverage the modest top-line improvement. The wide spread, combined with the recent downgrade pattern and the stock's 1.184 beta, suggests investors should expect continued volatility; the consensus target of $135.79 is only modestly above the 52-week high of $140.30, implying analysts see limited near-term upside beyond the recent trading range unless a genuine cyclical inflection is confirmed.
Bulls vs Bears: MHK Investment Factors
The bear case currently has stronger evidence due to persistent margin compression (gross margin 23.5% vs. 25%+ in 2024), weak profitability (net margin 4.3%, ROE 4.4%), and recent analyst downgrades, despite the stock trading at deep-value multiples (P/B 0.81x, P/S 0.63x). The bull case rests on the 8.0% revenue growth inflection and earnings leverage (EPS $1.91 vs. $1.16 YoY), but these are early signs against a backdrop of negative 1-year relative performance (-25.5% vs. SPY) and a stalled rally. The single most important tension is whether the 8% revenue growth is sustainable and can drive gross margin recovery toward 25%+, which would justify multiple expansion; if margins fail to recover, the cheap valuation could prove to be a value trap. The market is clearly pricing in skepticism, as evidenced by the forward PE of 12.6x versus trailing 18.3x, implying expectations of earnings growth that have yet to materialize in reported results.
Bullish
- Revenue growth inflects to 8.0% YoY: Q1 2026 revenue of $2.729 billion rose 8.0% year over year from $2.526 billion, the strongest top-line comparison in several periods and a clear acceleration from flat-to-down trends in 2024 and early 2025. This suggests the flooring cycle may finally be inflecting, with hard-surface categories like ceramic and LVT leading the recovery.
- Deep value on book and sales: The stock trades at a P/B of 0.81x and P/S of 0.63x, both near the bottom of their multi-year ranges (P/B range 0.71x-1.54x; P/S historically 2.0x-4.6x). EV/EBITDA of 7.4x is well below typical building-products peers at 8-12x, implying the market is pricing in a cyclical trough that historically has preceded mean-reversion rallies.
- Earnings leverage on modest growth: Q1 2026 EPS of $1.91 versus $1.16 a year ago represents 65% growth on just 8% revenue growth, demonstrating significant operating leverage as volumes recover. Net income of $117.1 million more than doubled from $72.6 million in Q1 2025, and forward PE of 12.6x versus trailing 18.3x implies the market expects this earnings momentum to continue.
- Conservative balance sheet with strong coverage: Debt-to-equity of 0.29, current ratio of 2.19, and interest coverage of roughly 50x indicate minimal financial risk. The company holds $872.3 million in cash, repurchased $64.7 million of stock in Q1 2026, and repaid $92.5 million of debt, signaling confidence in liquidity and capital allocation flexibility.
Bearish
- Gross margin compression persists: Gross margin of 23.5% in Q1 2026 is down from 25.5% in Q2 2025 and 25.4% in Q3 2025, reflecting input-cost inflation, pricing pressure, and underutilized capacity. The gap to the 25-26% levels of 2024 highlights how much margin recovery is needed to restore normalized profitability.
- Weak profitability and returns: Net margin of 4.3% and operating margin of 4.7% are thin for a company of Mohawk's scale, while ROE of 4.4% and ROA of 3.7% are well below what higher-quality industrials earn. These metrics suggest the company is not yet generating adequate returns on its asset base.
- Recent analyst downgrades signal caution: B of A Securities downgraded to Neutral from Buy on April 20, 2026, and Baird downgraded to Neutral from Outperform on April 21, 2026, while Barclays, Wells Fargo, and Evercore ISI maintain Equal Weight/In Line ratings. The consensus recommendation mean of 2.47 is a lukewarm Buy, reflecting skepticism about the recovery's durability.
- Negative long-term relative performance: The stock is down 9.3% over the past year versus SPY's +16.2%, a relative strength of -25.5%. The 1-month relative strength of -6.3% shows recent underperformance, and the 9.5% drawdown from the August 14 high of $140.10 to $126.79 indicates the rally has stalled.
MHK Technical Analysis
Mohawk is in a broad recovery trend that has stalled over the past month. The stock is up 17.8% over three months and 23.6% over six months, but the 1-year change is -9.3%, meaning the longer-term trend is still negative even after the recent rally. At $126.79, the stock sits at roughly 71.6% of its 52-week range (52-week low of $92.99, high of $140.30), positioning it in the upper-middle portion of the range — not overextended at the highs, but no longer a deep-value falling knife either. The 1-year underperformance versus SPY (+16.2%) is stark, with relative strength of -25.5% over 12 months, confirming that this is a recovery story still trying to prove itself rather than a sustained leader.
Recent momentum has decelerated sharply and now diverges from the medium-term trend. The stock is down 7.4% over the past month versus a 1.1% decline for SPY, producing relative strength of -6.3% for the month, even as the 3-month relative strength remains a strong +14.8%. This divergence — strong 3-month, weak 1-month — suggests the August rally to the $140 area was overextended and is now undergoing a mean-reversion pullback rather than a full trend reversal, especially since the stock remains well above its 52-week low. The pullback from the $140.10 August 14 high to $126.79 represents a roughly 9.5% drawdown, a normal correction within an uptrend, but the failure to hold the $130 level is a caution flag. Volume of about 1.03 million shares is modest, and with a short ratio of 4.43 days, there is a meaningful short base that could amplify moves in either direction.
Key technical levels are well defined. Immediate support sits at the $124-$125 area (the September 1 low of $125.04 and September 10 close of $124.24), with stronger support at the 52-week low of $92.99; resistance is the 52-week high of $140.30, and a breakout above that level would signal the recovery has legs and likely open the door to the analyst high target of $155. A breakdown below $124 would put the August breakout in jeopardy and shift focus back toward the $110-$115 zone. With a beta of 1.184, Mohawk is about 18% more volatile than the market, meaning position sizing should account for above-market drawdown risk; the maximum drawdown of -32.5% over the period underscores that this is not a low-volatility holding.
Beta
1.18
1.18x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$93-$140
Price range past year
Annual Return
-5.0%
Cumulative gain past year
| Period | MHK Return | S&P 500 |
|---|---|---|
| 1m | -6.8% | -1.0% |
| 3m | +12.3% | +2.0% |
| 6m | +31.1% | +17.4% |
| 1y | -5.0% | +15.0% |
| ytd | +15.1% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MHK Fundamental Analysis
Mohawk's revenue trajectory has inflected positively after a prolonged trough. The most recent quarter (ended April 4, 2026) delivered revenue of $2.729 billion, up 8.0% year over year from $2.526 billion in the prior-year quarter, a clear acceleration from the roughly flat-to-down comparisons of 2024 and early 2025. Sequentially, revenue rose from $2.700 billion in Q4 2025 and $2.758 billion in Q3 2025, indicating stabilization at a higher base. By segment, Global Ceramic is the largest contributor at $1.081 billion, followed by Carpet and Resilient at $898 million and Laminate and Wood at $448 million; the ceramic and LVT categories are the key growth engines tied to hard-surface flooring demand, while the legacy carpet business remains the drag. The 8.0% growth rate, if sustained, would mark a genuine cyclical recovery, but it comes against very easy prior-year comparisons, so the market is right to question its durability.
Profitability remains the central weakness. Q1 2026 net income was $117.1 million on revenue of $2.729 billion, a net margin of just 4.3%, and gross margin of 23.5% — down from 25.5% in Q2 2025 and 25.4% in Q3 2025, showing clear compression over the past year. Operating margin of 4.7% and EBITDA margin of 10.7% are thin for a company of Mohawk's scale, reflecting input-cost inflation, pricing pressure, and underutilized manufacturing capacity. The good news is that the loss trajectory has reversed: net income of $117.1 million in Q1 2026 compares favorably to $72.6 million in Q1 2025, and EPS of $1.91 versus $1.16 a year ago shows meaningful earnings leverage on modest revenue growth. Still, the gap between gross margin of 23.5% and the 25-26% levels seen in 2024 highlights how much margin recovery is needed to restore normalized profitability.
Balance sheet and cash flow metrics are a relative bright spot. Debt-to-equity is a conservative 0.29, the current ratio is a healthy 2.19, and interest coverage is very strong at roughly 50x in the most recent quarter, indicating low financial risk. Free cash flow on a trailing-twelve-month basis is $709.4 million, though Q1 2026 free cash flow was only $7.8 million due to a $166.4 million working-capital build (largely receivables and inventory) and $102.3 million of capex; operating cash flow of $110.1 million covered capex but left little excess. ROE of 4.4% and ROA of 3.7% are low, reflecting compressed earnings rather than balance-sheet stress. The company has $872.3 million of cash, repurchased $64.7 million of stock in Q1 2026, and repaid $92.5 million of debt, signaling confidence in liquidity but also limited internal cash generation to fund aggressive growth — the low payout ratio of 0% and no dividend mean all capital is being reinvested or returned via buybacks.
Quarterly Revenue
$2.7B
2026-04
Revenue YoY Growth
+8.0%
YoY Comparison
Gross Margin
23.5%
Latest Quarter
Free Cash Flow
$709400000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MHK Overvalued?
Because Mohawk is profitable (Q1 2026 net income of $117.1 million), the PE ratio is the primary metric. The trailing PE is 18.3x, while the forward PE is 12.6x — a roughly 31% discount — implying the market expects earnings to grow meaningfully over the next year, consistent with the consensus EPS estimate of $15.73 (though that figure appears to reflect a different share/earnings basis than the quarterly EPS of $1.91). The PS ratio of 0.63x and EV/Sales of 0.81x are low in absolute terms, and the PEG ratio of -0.68 is distorted by negative historical growth, so it should be disregarded. The wide gap between trailing and forward PE is the key signal: investors are paying up for a recovery that has not yet fully materialized in reported earnings.
Relative to the broader Consumer Cyclical/Furnishings industry, Mohawk screens cheap on most metrics. A PS ratio of 0.63x and EV/EBITDA of 7.4x are below typical building-products and furnishings multiples (many peers trade at 8-12x EV/EBITDA), and the P/B of 0.81x means the stock trades below book value — unusual for a market leader with $8.8 billion of revenue scale. The discount is partly justified by inferior profitability: net margin of 3.4% and operating margin of 4.7% are well below what higher-quality industrials earn, and ROE of 4.4% is weak. However, the forward PE of 12.6x versus a market multiple in the high teens suggests the market is pricing in either skepticism about the recovery or a cyclical discount that could compress if margins normalize.
Historically, Mohawk's valuation has been volatile with the cycle. The PE ratio ranged from about 11.2x (Q2 2025) to 40.2x (Q4 2025, when earnings collapsed) and even negative in loss quarters (Q3 2023, Q3 2022), while the PS ratio has ranged from roughly 2.0x in 2023 to 4.6x in 2021 — the current PS of 0.63x is dramatically below that historical band, though the historical ratios appear to use a different share count basis. The P/B of 0.81x is near the low end of its multi-year range (0.71x-1.54x), and the EV/EBITDA of 7.4x is below the 2024-2025 average in the low-to-mid teens. On a price-to-book and price-to-sales basis, Mohawk is trading near the bottom of its own historical range, which historically has coincided with cyclical troughs and has preceded mean-reversion rallies — but it can also reflect genuine fundamental deterioration if the housing cycle fails to recover.
PE
18.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.4x
Enterprise Value Multiple
Investment Risk Disclosure
Mohawk's financial and operational risks are centered on margin pressure and cash flow generation. Gross margin of 23.5% in Q1 2026 is down from 25.5% in Q2 2025, and net margin of 4.3% is thin, reflecting input-cost inflation and underutilized capacity. Free cash flow in Q1 2026 was only $7.8 million due to a $166.4 million working-capital build, leaving little excess after $102.3 million of capex. While debt-to-equity of 0.29 and interest coverage of 50x indicate low financial risk, the company's ability to fund growth and buybacks depends on restoring profitability. Revenue concentration in the Global Ceramic segment ($1.081 billion of $2.729 billion) and exposure to the cyclical housing market add operational risk.
Market and competitive risks include valuation compression if the recovery stalls, as the stock trades at a forward PE of 12.6x but has a beta of 1.184, making it 18% more volatile than the market. The wide analyst target range ($115-$155) and recent downgrades (B of A and Baird to Neutral in April 2026) highlight disagreement about the recovery's strength. Competitive pressures in flooring from lower-cost imports and pricing pressure could limit margin recovery. Macro sensitivity is high given the housing cycle dependence; a slowdown in residential remodeling or new construction would directly impact demand. Sector rotation risk is also present, as consumer cyclical stocks can underperform if interest rates remain elevated.
The worst-case scenario involves a stall in the housing recovery, continued gross-margin compression below 23%, and earnings failing to leverage revenue growth. This could drive the stock toward the 52-week low of $92.99 or the analyst low target of $115, representing a decline of approximately -27% to -9% from the current price of $126.79. The maximum drawdown over the past period was -32.5%, indicating that a severe downturn could result in losses of over 30%. If the August breakout fails and the stock breaks below $124 support, the next support zone is $110-$115, and a move to the 52-week low would imply a -27% loss. Investors should be prepared for significant volatility given the beta of 1.184 and the stock's history of large drawdowns.
FAQ
The key risks ranked by severity are: 1) Margin compression — gross margin of 23.5% is down from 25.5% in Q2 2025, and further compression would pressure earnings; 2) Cyclical housing exposure — a stall in the housing recovery would directly impact revenue, which grew 8.0% YoY in Q1 2026 but may not be sustainable; 3) Weak profitability — net margin of 4.3% and ROE of 4.4% leave little buffer for operational missteps; 4) Valuation compression — with a beta of 1.184, the stock is 18% more volatile than the market, and a breakdown below $124 support could accelerate losses toward the 52-week low of $92.99. Additionally, recent analyst downgrades (B of A and Baird to Neutral) signal waning confidence.
The 12-month forecast has three scenarios: bull case (25% probability) targeting $145-$155 if the housing recovery accelerates and gross margin recovers above 25%; base case (55% probability) targeting $130-$140 if growth moderates and margins stabilize around 24%; bear case (20% probability) targeting $93-$115 if the recovery stalls and margins compress further. The base case is most likely, assuming gradual housing improvement and stable analyst estimates. The key assumption is that revenue growth remains positive and gross margin does not deteriorate below 23%. The analyst average target of $135.79 aligns with the base case, implying 7.1% upside.
MHK appears undervalued on asset-based and sales metrics, with P/B of 0.81x and P/S of 0.63x near the bottom of their historical ranges (P/B 0.71x-1.54x; P/S historically 2.0x-4.6x). EV/EBITDA of 7.4x is below peers at 8-12x, and the forward PE of 12.6x is a 31% discount to the trailing PE of 18.3x, implying expected earnings growth. However, the discount is partly justified by inferior profitability: net margin of 4.3% and ROE of 4.4% are well below higher-quality industrials. The market is pricing in skepticism about the recovery, as evidenced by the wide analyst target range and recent downgrades. If margins normalize toward 25%, the stock could re-rate higher; if not, it may remain cheap.
MHK is a good buy only for value-oriented investors with a long time horizon and tolerance for volatility. The stock trades at a deep discount to book (P/B 0.81x) and sales (P/S 0.63x), with a forward PE of 12.6x, implying the market expects earnings growth. Analyst consensus target of $135.79 offers 7.1% upside, but the wide range ($115-$155) and recent downgrades to Neutral signal uncertainty. The biggest downside risk is a stall in the housing recovery, which could push the stock toward the 52-week low of $92.99 (-27%). For risk-averse investors, the weak profitability (net margin 4.3%, ROE 4.4%) and negative 1-year relative performance (-25.5% vs. SPY) make it less attractive. It is a speculative cyclical bet, not a core holding.
MHK is better suited for long-term investment (minimum 2-3 years) given its cyclical nature and the early stage of the recovery. The stock has a beta of 1.184, meaning it is 18% more volatile than the market, and a maximum drawdown of -32.5%, so short-term trading carries high risk. The company pays no dividend (payout ratio 0%), so returns depend entirely on capital appreciation. Earnings visibility is low, with a wide analyst target range ($115-$155) and recent downgrades. Long-term investors can benefit from the cyclical recovery and potential multiple expansion if margins normalize, but they must tolerate significant volatility. A suggested minimum holding period is 2 years to allow the housing cycle to play out.